authors,title,journal,year,doi
"Ernst D, Baker PC, **Bot BM**, Crouthamel M, de Vries G, Ferguson I, Hixson JD, Malek LA, Mastrototaro JJ, Misra V, Ozcan A, Sacks L, Wang P","Mobile health: the power of wearables, sensors, and apps to transform clinical trials","Annals of the New York Academy of Sciences","2016","10.1111/nyas.13117"
"**Bot BM**, Suver C, Chaibub Neto E, Kellen M, Klein A, Bare C, Doerr M, Pratap A, Wilbanks J, Dorsey ER, Friend S, Trister A","The mPower study, parkinson disease mobile data collected using researchKit","Nature Scientific Data","2016","10.1038/sdata.2016.11"
"Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, **Bot BM**, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S","The consensus molecular subtypes of colorectal cancer","Nature Medicine","2015","10.1038/nm.3967"
"Dienstmann R, Jang IS, **Bot B**, Friend S, Guinney J","Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors","Cancer Discovery","2015","10.1158/2159-8290.CD-14-1118"
"Derry J, Mangravite L, Suver C, Furia M, Henderson D, Schildwachter X, **Bot B**, Izant J, Sieberts S, Kellen M, Friend S","Developing predictive molecular maps of human disease through community-based modeling","Nature Genetics","2012","10.1038/ng.1089"
"Oberg A, **Bot B**, Grill D, Poland G, Therneau T","Technical and biological variance structure in mRNA-Seq data: life in the real world","BMC Genomics","2012","10.1186/1471-2164-13-304"
"**Bot B**, Eckel-Passow J, LeGrand, Hilton T, Cheville J, Igel T, Parker A","Expression of Endothelin-2 and Localized Clear Cell Renal Cell Carcinoma","Hum Pathol","2012","10.1016/j.humpath.2011.07.011"
"Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, **Bot B**, Grothey A, Buyse A, de Gramont A","Two or three tear disease free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07, and C89803","Eur J Cancer","2011","10.1016/j.ejca.2010.12.015"
"de Gramont A, Hubbard J, Shi Q, O’Connell M, Buyse M, Benedetti J, **Bot B**, O’Callaghan C, Yothers G, Goldberg R, Blanke C, Benson A, Deng Q, Alberts S, Andre T, Wolmark N, Grothey A, Sargent D","Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set","J Clin Oncol","2010","10.1200/JCO.2009.23.1407"
"Sargent D, Kohne C, Sanoff H, **Bot B**, Seymour M, de Gramont A, Porschen R, Saltz L, Rougier P, Tournigand C, Douillard J, Stephens R, Grothey A, Goldberg R","Pooled safety and efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials using individual patient data from 6,286 patients with metastatic colorectal cancer","J Clin Oncol","2009","10.1200/JCO.2008.20.2879"
